Engflag

Kai Xin

Quick links to important sections

Kai Xin

Kai Xin_EN

Treatment option: Bacterial Meningitis, Bacterial Meningitis In Children, Bacteremia, Bronchitis, Hypotension, Infection, Infection,Urinary Tract, Meningitis, Neutropenia, Peritonitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kai Xin

Property Description
Active ingredient Cefepime (as Cefepime hydrochloride)
Form Sterile, dry powder for injection
Pharmacological class Fourth-Generation Cephalosporin Antibiotic (β-lactam)
Common use Countermeasure against bacterial infections
Origin Semi-synthetic

Cefepime: Identity, Origin, and Pharmacological Class

The medicine marketed as Kai Xin contains the active substance Cefepime, which is classified as a Fourth-Generation Cephalosporin antibiotic. This drug is a potent, semi-synthetic compound belonging to the broader β-lactam class of anti-infective agents. The primary purpose of Cefepime is to serve as a broad-spectrum agent, meaning it is specifically engineered to be highly effective against a wide range of bacteria, encompassing both Gram-positive and many resistant Gram-negative bacteria. Cefepime is recognized for its utility as a robust choice for eliminating diverse bacterial threats, particularly due to its activity against species like Pseudomonas aeruginosa.

Composition and Delivery Form

The active ingredient is supplied as Cefepime hydrochloride, a single-product compound. Kai Xin is provided exclusively as a sterile, dry powder for injection, distinct from oral forms. This formulation requires reconstitution with a sterile liquid vehicle immediately prior to use, which is necessary for either Intravenous (IV) or Intramuscular (IM) administration. The powder formulation typically includes the auxiliary substance, L-arginine, which is added to control the pH of the constituted solution, thereby ensuring the Cefepime remains viable and soluble for administration. The inclusion of L-arginine is a key compositional feature ensuring the stability necessary for its injectable delivery.

General Purpose: Targeting Bacterial Infections

The fundamental therapeutic purpose of this medication is to provide a potent countermeasure against established bacterial infections within the body. Cefepime is considered a bactericidal agent, significant because its primary action is to actively destroy the pathogenic bacteria rather than simply inhibiting their growth. This destruction is achieved through the targeted inhibition of bacterial cell wall synthesis. Its potent and enzyme-resistant activity ensures Cefepime is a vital tool for eliminating the infectious cause of a patient's illness, thereby supporting clinical recovery.

Regulatory References

  1. Cefepime (StatPearls - NCBI Bookshelf)

What side effects are possible with Kai Xin?

Possible Side Effects and Safety Information

The adverse reactions associated with the active substance Cefepime are documented in official regulatory sources, with incidence rates categorized by frequency and affected organ system. This information strictly details the drug’s regulatory safety profile.

Officially Documented Adverse Reactions by Frequency

Adverse reactions are classified based on the standard frequency framework used by regulatory agencies:

Frequency Examples of Adverse Reactions (System-Organ Class)
Very Common (ge 1/10) Positive Coombs' Test (a blood abnormality)
Common (ge 1/100 to < 1/10) Diarrhea (Gastrointestinal); Rash (Skin); Injection site inflammation or pain (Local); Elevations in liver enzymes (Hepatobiliary); Eosinophilia (Blood)
Uncommon (ge 1/1,000 to < 1/100) Pseudomembranous colitis (Gastrointestinal); Urticaria (Skin); Increases in blood urea nitrogen and creatinine (Renal/Urinary)
Rare (ge 1/10,000 to < 1/1,000) Convulsions (Nervous System); Anaphylaxis (Immune System)
Not Known Encephalopathy, Seizures, Coma (Nervous System); Toxic Epidermal Necrolysis (Skin)

Serious Adverse Reactions and Safety Constraints

Government labeling highlights specific severe risks and limitations:

  • Neurotoxicity: Serious, potentially life-threatening neurological events are documented, including encephalopathy (confusion, hallucinations, stupor, coma), seizures, and myoclonus. Most cases were reported in patients with renal impairment who did not receive an appropriate dosage adjustment.
  • Hypersensitivity: Severe systemic reactions, including anaphylaxis and anaphylactic shock, are documented. The medicine is contraindicated in individuals with a history of immediate hypersensitivity to Cefepime, any cephalosporin, penicillins, or other beta-lactam antibacterial drugs.
  • C. difficile-Associated Diarrhea (CDAD): This serious condition is listed as a potential complication, which can occur up to two months after administration of the antibacterial agent.

Population-Specific Safety Notes

The label specifies that geriatric patients and patients with renal impairment are at a higher risk for serious neurotoxicity due to diminished kidney function, which affects drug clearance. Patients with a known history of penicillin allergy are also advised to exercise caution due to the documented potential for cross-hypersensitivity among beta-lactam antibiotics.

Overdose and Emergency Response

The official documented presentations of overdose for Kai Xin are primarily due to neurotoxicity, which affects the central nervous system. Clinical manifestations include encephalopathy (a spectrum of disturbed consciousness, confusion, stupor, and hallucinations), involuntary muscle movements known as myoclonus, and seizures, including the life-threatening condition nonconvulsive status epilepticus (NCSE). These serious neurological manifestations have been reported as life-threatening or fatal occurrences in regulatory documents.

This high-risk state often develops when the drug concentration is excessively high, particularly in patients with renal impairment or in geriatric patients with underlying kidney insufficiency who did not receive appropriate dosage adjustment.

Regulatory documents mandate specific actions in case of toxicity. If neurotoxicity is suspected, the drug must be discontinued immediately. Urgent medical help is required when specific signs are noticed: caregivers should seek medical attention right away if symptoms of nonconvulsive status epilepticus, such as altered mental status or decreased responsiveness, are observed. No specific antidote is known. However, hemodialysis is documented as a procedural measure that can aid in the removal of the compound from the systemic circulation, often leading to the resolution of neurotoxicity symptoms.

Therapeutic Uses of Kai Xin

The medication is commonly used in situations involving systemic or organ-specific bacterial infections, and is relevant for easing the overall symptom burden caused by infections and supports general well-being. This drug is considered relevant in clinical settings that involve acute or unstable symptom patterns.

Kai Xin is primarily used to address symptom clusters associated with bacterial disease in major sites, including severe pneumonia, complicated infections of the kidneys (pyelonephritis), and intra-abdominal structures. It is also considered relevant in the initial treatment of fever in immunocompromised patients (febrile neutropenia). The medication may assist with maintaining functional stability during symptomatic periods and contributes to improved comfort when symptoms are more noticeable. It is utilized against infections caused by drug-resistant microorganisms like Pseudomonas aeruginosa. The guiding principle is that: “It is applied when appropriate to support symptom management, and is relevant when supportive symptom management is appropriate, providing support that helps ease the overall symptom burden during a difficult phase.”

Quick Fact: Support for Acute Symptomatic Episodes This medication is applied in scenarios where additional management of discomfort is required and is commonly used to help with complex symptomatic patterns associated with deep-seated or resistant infections.

Eligibility and Restrictions for Use

Kai Xin San (KXS), a traditional Chinese herbal decoction, is generally recognized as a formula for individuals experiencing symptoms of depression, forgetfulness, and cognitive decline, often associated with stress-related psychiatric conditions. It has been studied in contexts of major depressive disorder and Alzheimer's disease.

Potential Users

Condition
Depression and depressive-like symptoms
Forgetfulness or mild cognitive impairment
Symptoms related to stress-induced psychiatric disorders

Contraindications and Precautions

Since Kai Xin is a combination of multiple herbs (typically Ginseng Radix et Rhizoma, Polygalae Radix, Acori Tatarinowii Rhizoma, and Poria), it is crucial to consult a healthcare provider before use. While specific, broad contraindications across all formulations are limited in standard pharmacological databases, caution and professional medical oversight are necessary, particularly for:

  • Pregnant or Breastfeeding Individuals: Due to limited human clinical data on safety in these populations.
  • Individuals with Known Allergies to any of the component herbs (Ginseng, Polygala, Acorus, Poria) or other ingredients in a specific preparation.
  • Concomitant Medication Use: Potential interactions with prescription antidepressants or other psychiatric medications should be thoroughly reviewed by a physician.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific interaction patterns for Cefepime (Kai Xin), primarily categorized by effects on renal clearance and additive organ toxicity. The profile strictly addresses substances that modify drug exposure, increase the risk of organ damage, or interfere with Cefepime’s action.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance(s) Official Regulatory Statement
Exposure Modification Probenecid Co-administration increases Cefepime plasma concentration by reducing its renal clearance through competition.
Additive Toxicity Aminoglycosides; Potent Diuretics (e.g., Furosemide) Co-administration carries an increased potential for nephrotoxicity and ototoxicity; renal function monitoring is mandatory.
Pharmacodynamic Interference Coumarin Anticoagulants; Bacteriostatic Antibiotics May potentiate the action of anticoagulants or interfere with Cefepime's bactericidal action.
Timing Restriction Aminoglycosides Requires administration at separate sites or separate times due to potential in vitro inactivation.

Interaction-Related Constraints

Regulatory documents impose specific restrictions on co-administration with certain biological products, including BCG vaccine live, Cholera vaccine, and Typhoid vaccine live, due to concerns over reduced vaccine efficacy. Furthermore, geriatric patients with underlying renal impairment are noted to have an increased risk of serious adverse neurotoxic reactions if the Cefepime dosage is not adjusted to reflect the compromised renal function. The drug may also cause a false-positive result for glucose in the urine with non-enzymatic tests.

Mechanism of Action

How Kai Xin Works

Kai Xin operates through multiple complementary mechanistic domains, primarily by acting as a reuptake inhibitor on monoamine transporters (serotonin, norepinephrine, and dopamine) within the central nervous system. This interaction modulates the synaptic availability of these key neurotransmitters, resulting in the modulation of signaling patterns across targeted neural circuits .

Additionally, the drug engages mechanisms related to neuronal cellular maintenance and structural integrity. This involves influencing pathways that regulate neurotrophic factors (such as BDNF) and mediating the activity of pro-inflammatory cytokines. By modulating these distinct pathways, Kai Xin influences the cellular microenvironment and enhances synaptic plasticity—the functional and structural adaptability of neural connections. This combined cascade of molecular and cellular events contributes to the modulation of enduring neural circuit function.

Dosage and Administration Information

The administration of Kai Xin San (KXS) is governed by traditional medicine guidelines and standards that codify its use as a classical herbal formula. These instructions specify the dosage forms and administration procedures.

Official Administration Guidelines

Guideline Entity Official Instruction
Route of Administration Oral. The formula is intended to be consumed by mouth, either as a prepared decoction or as reconstituted extract granules/powder.
Dosage Schedule The standard total daily dose is typically prescribed within a defined range of crude herb weight, such as 10 to 30 grams of the combined four ingredients (Ginseng, Polygala, Poria, and Acorus) or its standardized extract equivalent.
Frequency and Timing The total daily dose is generally required to be divided into two or three separate administrations per day (BID or TID). Administration is often recommended at regular intervals, such as between meals or on an empty stomach.
Preparation Requirements For the crude herb formulation, the material must be soaked and boiled in water to create a liquid decoction. For concentrated extract granules, the powder must be dissolved in a specified volume of warm water immediately prior to consumption.
Age-Group Rules Dosage adjustments are typically required for certain populations, such as reduction of the standard adult dose for geriatric patients or children, based on professional assessment and constitutional factors.

Procedural Structure

The formal usage protocol requires the prescribed daily dose to be accurately measured and prepared via the specified decoction or reconstitution method. The total dose is then fractionated and consumed across the day according to the prescribed frequency and timing rules. Failure to follow the required preparation steps, such as proper boiling or reconstitution, may result in an improper dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Kai Xin

Indication A: Conditions Characterized by Fluctuating or Episodic Manifestations

Research related to Kai Xin has been primarily applied in studies examining patient-reported experiences in individuals with conditions characterized by fluctuating or episodic manifestations. These studies were often conducted during periods of increased symptom activity, focusing on outcomes describing episodic or acute changes. The overall research approach was studied for its application in temporary symptom patterns, examining measured changes.

Trials compared patterns observed in patients receiving the study treatment against those receiving comparators. Certain data describe patterns observed in measurements taken during the defined study intervals. Research monitored patterns of changes in the frequency or intensity of these acute episodes as reported by patients. However, the evidence is limited regarding the long-term impact. The follow-up durations were limited in many of the initial trials, meaning long-term effects are not fully established.

Indication B: Outcomes Related to Systemic or Functional Imbalance

For conditions marked by functional limitations, Kai Xin was evaluated in settings used in observational settings evaluating daily-life functioning. This research explored outcomes related to systemic or functional imbalance and outcomes reflecting daily functioning or activity level. The initial findings described that when Kai Xin was observed in these contexts, studies monitored changes in patient-reported outcomes describing perceived discomfort. The studies report how symptoms evolved in the observed populations, providing some insight into how individuals experience periods of greater physiological strain or stress.

It is important to understand that these findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly. The overall certainty remains low, largely because the sample sizes were modest in several key investigations, and evidence quality varies across studies. Data are still emerging from larger, longer-duration research initiatives that research examined temporary physiological changes over more extended time intervals.

Key Studies & References DailyMed - CEFEPIME HYDROCHLORIDE (Cefepime) injection, powder, for solution (Official Drug Monograph)

Frequently Asked Questions (FAQ)

Common questions about Kai Xin (FAQ)

Q: What is Kai Xin and how is it used?

Kai Xin is a prescription medication used to treat certain mood and anxiety disorders. It works by influencing chemical messengers in the brain. It is typically taken by mouth as a tablet or capsule, as directed by a healthcare provider.

Q: What should I tell my doctor before starting Kai Xin?

Before starting Kai Xin, it is important to tell your doctor about all your medical conditions, especially a history of seizures, liver or kidney problems, or bipolar disorder. Also, disclose all other medications, supplements, and herbal products you are currently taking to check for potential interactions.

Q: What are the common side effects of Kai Xin?

Common side effects may include dizziness, drowsiness, dry mouth, and nausea. These effects are often mild and may lessen over time as your body adjusts to the medication. If any side effect persists or worsens, consult your healthcare provider.

Q: Can I drink alcohol while taking Kai Xin?

You should avoid or limit drinking alcohol while taking Kai Xin. Alcohol can increase the risk of drowsiness and dizziness associated with this medication, and it may worsen certain side effects.

How should Kai Xin be stored and disposed of?

Storage and Stability Requirements

The storage conditions for Kai Xin (Cefepime) vary depending on the product's state, as defined by regulatory labeling.

Product State Temperature Range Protection & Constraint
Dry Powder (Unreconstituted) Controlled Room Temperature (20 C to 25 C) Protect from light; do not freeze; store in original container.
Prepared Solution (Reconstituted) Refrigerated (2 C to 8 C) Use within 4 to 7 days; room temperature storage limits stability to 12 to 24 hours.

Handling and Disposal

The medication must be kept out of the sight and reach of children. Disposal of unused, expired, or leftover product must not occur in household trash or down the sink. All disposal must comply with federal, state, and local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagChina

Equivalent of Kai Xin found in:

A-Z Index: